SCHEMBL10000338

SCHEMBL10000338

NCCNC(=O)CCCCC1SCC2NC(=O)NC21

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.72
CA12 O43570 6/20 0.66
CA1 P00915 6/20 0.66
CA2 P00918 6/20 0.66
CA9 Q16790 6/20 0.66
PKM P14618 2/20 0.65
MEN1 O00255 1/20 0.65
ABL1 P00519 1/20 0.65
LMNA P02545 1/20 0.65
IDE P14735 1/20 0.65
MAPK1 P28482 1/20 0.65
KMT2A Q03164 1/20 0.65
RIN1 Q13671 1/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
HLCS P50747 3/20 0.57
F2 P00734 1/20 0.57
PRSS1 P07477 1/20 0.57
PRSS2 P07478 1/20 0.57
PRSS3 P35030 1/20 0.57
TPSAB1 Q15661 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3256514 1.00 TDP1 (0.72) TDP1CA12CA1CA2CA9
SCHEMBL10140274 1.00 TDP1 (0.72) TDP1CA12CA1CA2CA9
SCHEMBL30821562 1.00 TDP1 (0.72) TDP1CA12CA1CA2CA9
SCHEMBL26598596 1.00 TDP1 (0.72) TDP1CA12CA1CA2CA9
SCHEMBL25014977 1.00 TDP1 (0.72) TDP1CA12CA1CA2CA9
SCHEMBL24420141 1.00 TDP1 (0.72) TDP1CA12CA1CA2CA9
SCHEMBL15895090 1.00 TDP1 (0.72) TDP1CA12CA1CA2CA9
Hydrochloric Acid SCHEMBL8147632 0.99 TDP1 (0.70) TDP1CA12CA1CA2CA9
Bromide SCHEMBL2678585 0.99 TDP1 (0.70) TDP1CA12CA1CA2CA9
Ethylenediamine SCHEMBL16679417 0.99 TDP1 (0.70) TDP1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026107515-A1 INCRETIN HORMONE COMPOSITIONS AND METHODS USING SAME DIASOME PHARMACEUTICALS, INC. (US) 2026-05-21 WO claimed
CN-122042600-A Circulating tumor DNA detection platform based on quasi-continuous domain constraint state mode super-structured grating 北京大学 2026-05-15 CN claimed
CN-119269809-A Assay kit for quantitatively detecting estradiol 南京颐兰贝生物科技有限责任公司 2025-01-07 CN claimed
CN-118376793-A Method for detecting Alzheimer disease related protein in human blood 杭州赛基生物科技有限公司 2024-07-23 CN claimed
WO-2023154852-A1 ANTIBODY BARCODED BEADS AND USES THEREOF CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-08-17 WO claimed
EP-2552202-B1 METHODS AND COMPOSITIONS FOR WEIGHT LOSS SDG INC (US) 2023-07-26 EP claimed
CN-116479049-A Method for improving gene editing efficiency by optimizing gene knock-in and delivery modes 西安基恩科生物科技有限责任公司 2023-07-25 CN claimed
CN-115290886-A Multi-detection diagnosis tool, method and application of cytokines at different concentration levels 江苏省人民医院(南京医科大学第一附属医院) 2022-11-04 CN claimed
CN-114681619-A Aptamer compound based on Biotin-SA and application thereof 上海交通大学医学院附属仁济医院 2022-07-01 CN claimed
EP-3952904-A1 LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS SDG, Inc. (US) 2022-02-16 EP claimed
WO-2026107515-A1 INCRETIN HORMONE COMPOSITIONS AND METHODS USING SAME DIASOME PHARMACEUTICALS, INC. (US) 2026-05-21 WO disclosed
CN-122042600-A Circulating tumor DNA detection platform based on quasi-continuous domain constraint state mode super-structured grating 北京大学 2026-05-15 CN disclosed
CN-122010928-A PCSK9 inhibitor and application thereof 江苏柯菲平医药股份有限公司 2026-05-12 CN disclosed
CN-122012807-A LAMP primer composition for nucleic acid chromatography, IBV detection test strip, kit, application of LAMP primer composition and kit and method for detecting IBV 合肥善本生物科技有限公司 2026-05-12 CN disclosed
US-20260120799-A1 METHODS AND SYSTEMS FOR PREDICTION OF HLA EPITOPES BIONTECH US INC (US) 2026-04-30 US disclosed
US-20090253149-A1 Novel Chemistry Used in Biosensors OHMX CORPORATION (US) 2009-10-08 US disclosed
US-20090209048-A1 Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same SAMSUNG ELECTRONICS CO., LTD. (KR) 2009-08-20 US disclosed
US-20090209048-A1 Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same SAMSUNG ELECTRONICS CO., LTD. (KR) 2009-08-20 US disclosed
US-7429560-B2 calpain inhibitors, preferably peptide alpha -ketoamides for pathologies of the peripheral nervous system such as neuropathy, degeneration, or calcium-induced cell injury GEORGIA TECH RESEARCH CORPORATION (US) 2008-09-30 US disclosed
EP-1084269-B1 NOVEL PEROXIDASE SUBSTRATES AND THEIR USE IN CATALYZED REPORTER DEPOSITION PERKINELMER LAS INC (US) 2007-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260120799-A1 METHODS AND SYSTEMS FOR PREDICTION OF HLA EPITOPES MICA, HLA-DRB1, TAP1 TDP1 1518/4885CA12 1020/4885CA1 2243/4885
US-20090209048-A1 Luminescence Biotin-Transition Metal Complex Conjugate, and Method of Amplifying Signal Using the Same BTD, HLCS, BPGM TDP1 3468/4885CA12 2975/4885CA1 3691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.